Italia markets closed

Guerbet SA (0ELV.L)

LSE - LSE Prezzo differito. Valuta in EUR.
Aggiungi a watchlist
18,18+0,30 (+1,68%)
Alla chiusura: 05:57PM BST
Schermo intero
Caricamento grafico interattivo in corso...
  • GlobeNewswire

    Guerbet: 2022 annual results

    2022 annual results Activity Annual revenue: €753.3 million, up 2.9% (-1.1% at CER1)Steady momentum in Asia and for Interventional Imaging; negative impact of production delays at the Raleigh site Profitability in line with expectations The restated EBITDA margin2 is 13.8%, at the top of the range of 13% to 14% announced last October 2023 outlook Revenue: expected growth above 5% on a like-for-like basis and at CER1Restated EBITDA margin3 expected around 11% before returning in 2024 to a level h

  • GlobeNewswire

    Guerbet: 2022 revenue

    2022 revenue Activity Annual revenue: €753.3 million, up +2.9% (-1.1% at CER1); production lags at the Raleigh site weighed on activity Profitability 2022 EBITDA margin: confirmation of the announced range of 13% to 14% (excluding extraordinary costs for the optimization of the operational structure and changes in the sales model in China) Outlook 2023 revenue: expected growth above 5% on a like-for-like basis and at CER Villepinte, February 9, 2023: Guerbet (FR0000032526 GBT), a global speciali

  • GlobeNewswire

    Guerbet: 2023 Strategic Priorities

    2023 Strategic Priorities Diagnostic Imaging: increase EluciremTM sales and strengthen international positionsInterventional Imaging: prioritise Lipiodol sales with the development of innovative indications Artificial Intelligence: execution of the roadmap for the emergence of a major AI player dedicated to medical imaging in oncology Villepinte, 16 January 2023: Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging has announced its strategic prior